Volume 17, Issue 2, Pages 243-256 (February 2016) Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data  Dr Claire L Vale, PhD, Sarah Burdett, MSc, Larysa H M Rydzewska, BSc, Laurence Albiges, MD, Prof Noel W Clarke, ChM, David Fisher, MSc, Prof Karim Fizazi, MD, Gwenaelle Gravis, MD, Prof Nicholas D James, PhD, Prof Malcolm D Mason, MD, Prof Mahesh K B Parmar, DPhil, Christopher J Sweeney, MBBS, Matthew R Sydes, CStat, Prof Bertrand Tombal, MD, Jayne F Tierney, PhD  The Lancet Oncology  Volume 17, Issue 2, Pages 243-256 (February 2016) DOI: 10.1016/S1470-2045(15)00489-1 Copyright © 2016 Vale et al. Open Access article distributed under the terms of CC-BY Terms and Conditions

Figure 1 Study flow chart CRPC=castrate-resistant prostate cancer. *One trial (STAMPEDE)8 is eligible to be included in both docetaxel and bisphosphonate comparisons. The Lancet Oncology 2016 17, 243-256DOI: (10.1016/S1470-2045(15)00489-1) Copyright © 2016 Vale et al. Open Access article distributed under the terms of CC-BY Terms and Conditions

Figure 2 Effect of addition of docetaxel to standard of care on survival and failure-free survival (A) Effect of the addition of docetaxel on survival in men with M1 disease. (B) Effect of the addition of docetaxel on failure-free survival in men with M1 disease. (C) Effect of the addition of docetaxel on survival in men with M0 disease. (D) Effect of the addition of docetaxel on failure-free survival in men with M0 disease. NA=event numbers by group not available. SOC=standard of care. The Lancet Oncology 2016 17, 243-256DOI: (10.1016/S1470-2045(15)00489-1) Copyright © 2016 Vale et al. Open Access article distributed under the terms of CC-BY Terms and Conditions

Figure 3 Effect of addition of bisphosphonates to standard of care on survival (A) Effect of the addition of bisphosphonates on survival in men with M1 disease. (B) Effect of the addition of zoledronic acid on survival in men with M1 disease. (C) Effect of the addition of bisphosphonates on survival in men with M0 disease. (D) Effect of the addition of zoledronic acid on survival in men with M0 disease. NA=event numbers by group not available. SOC=standard of care. The Lancet Oncology 2016 17, 243-256DOI: (10.1016/S1470-2045(15)00489-1) Copyright © 2016 Vale et al. Open Access article distributed under the terms of CC-BY Terms and Conditions